Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis-Reference-Cited by-同舟云学术

Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis

Published:2020-09 Issue: Volume:159 Page:105020
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Zheng Qiyan,Yang Huisheng,Sun Luying,Wei Ruojun,Fu Xinwen,Wang Yahui,Huang Yishan,Liu Yu Ning,Liu Wei Jing

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Pharmacology

Reference60 articles.

1. Chronic kidney disease: global dimension and perspectives;Jha;LANCET,2013

2. Prevalence of chronic kidney disease in the United States;Coresh;JAMA,2007

3. A rationale for an individualized haemoglobin target;Muirhead;Nephrol. Dial. Transplant.,2002

4. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients;Regidor;J. Am. Soc. Nephrol.,2006

5. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations;Collins;Nephrol. Dial. Transplant.,2003

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of hypoxia-inducible factor 1 in type 1 diabetes;Trends in Pharmacological Sciences;2024-09

2. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systematic review and network meta-analysis;Frontiers in Pharmacology;2024-07-10

3. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction;Life Sciences;2024-06

4. The Efficacy and Safety of Roxadustat for the Treatment of Posttransplantation Anemia: A Randomized Study;Kidney International Reports;2024-06

5. The comparison of four hypoxia-inducible factor prolyl hydroxylase inhibitors on drug potency and cost for treatment in patients with renal anemia;Clinical and Experimental Nephrology;2024-05-20